BioXcel Therapeutics Inc
NASDAQ:BTAI

Watchlist Manager
BioXcel Therapeutics Inc Logo
BioXcel Therapeutics Inc
NASDAQ:BTAI
Watchlist
Price: 2.13 USD -3.18%
Market Cap: 46.6m USD

Relative Value

The Relative Value of one BTAI stock under the Base Case scenario is 12.71 USD. Compared to the current market price of 2.13 USD, BioXcel Therapeutics Inc is Undervalued by 83%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BTAI Relative Value
Base Case
12.71 USD
Undervaluation 83%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
30
vs Industry
70
Median 3Y
54.8
Median 5Y
10.5
Industry
7.9
Forward
68.1
vs History
vs Industry
Median 3Y
-0.5
Median 5Y
-2.4
Industry
24
Forward
-0.3
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-2.8
Industry
21.6
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-3.2
Industry
23.7
vs History
vs Industry
67
Median 3Y
-0.2
Median 5Y
2.3
Industry
3.4
vs History
19
vs Industry
21
Median 3Y
95.3
Median 5Y
40.3
Industry
8.3
Forward
157.7
vs History
vs Industry
5
Median 3Y
208.4
Median 5Y
-74.2
Industry
10.3
vs History
vs Industry
Median 3Y
-1.4
Median 5Y
-1.9
Industry
6.7
Forward
-1.8
vs History
vs Industry
Median 3Y
-1.4
Median 5Y
-1.9
Industry
7.2
Forward
-1.9
vs History
vs Industry
Median 3Y
-1.2
Median 5Y
-1.7
Industry
8.2
vs History
vs Industry
Median 3Y
-1.2
Median 5Y
-1.7
Industry
6.7
vs History
vs Industry
43
Median 3Y
-12.2
Median 5Y
24.6
Industry
5.7

Multiples Across Competitors

BTAI Competitors Multiples
BioXcel Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
BioXcel Therapeutics Inc
NASDAQ:BTAI
42.6m USD 56.6 -0.6 -2 -2
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 111 463.2 -162 126.7 -196 873.6 -194 627
US
Abbvie Inc
NYSE:ABBV
394.3B USD 6.6 168.4 16.4 23.3
US
Amgen Inc
NASDAQ:AMGN
169.9B USD 4.7 24.2 17.6 17.6
US
Gilead Sciences Inc
NASDAQ:GILD
149B USD 5.1 18.2 12.2 12.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
110.9B USD 9.5 30.2 22.1 23.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 065.3 -527 -573.9 -558.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75B USD 5.2 16.2 15.1 17.1
AU
CSL Ltd
ASX:CSL
87.9B AUD 3.8 19.5 13.1 16.3
NL
argenx SE
XBRU:ARGX
47B EUR 15.2 35.8 62.1 63.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
54B USD 17 1 250.1 165 200.1
P/E Multiple
Earnings Growth PEG
US
BioXcel Therapeutics Inc
NASDAQ:BTAI
Average P/E: 195.3
Negative Multiple: -0.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 126.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.4
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.2
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.2
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
9%
1.8
AU
CSL Ltd
ASX:CSL
19.5
11%
1.8
NL
argenx SE
XBRU:ARGX
35.8
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 250.1
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
BioXcel Therapeutics Inc
NASDAQ:BTAI
Average EV/EBITDA: 40.4
Negative Multiple: -2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 873.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.4
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.6
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.2
7%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -573.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
11%
1.4
AU
CSL Ltd
ASX:CSL
13.1
8%
1.6
NL
argenx SE
XBRU:ARGX
62.1
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
165
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
BioXcel Therapeutics Inc
NASDAQ:BTAI
Average EV/EBIT: 46.7
Negative Multiple: -2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 627 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.3
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.6
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.2
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
13%
1.3
AU
CSL Ltd
ASX:CSL
16.3
11%
1.5
NL
argenx SE
XBRU:ARGX
63.8
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
200.1
N/A N/A